JP2023524102A5 - - Google Patents

Info

Publication number
JP2023524102A5
JP2023524102A5 JP2022566628A JP2022566628A JP2023524102A5 JP 2023524102 A5 JP2023524102 A5 JP 2023524102A5 JP 2022566628 A JP2022566628 A JP 2022566628A JP 2022566628 A JP2022566628 A JP 2022566628A JP 2023524102 A5 JP2023524102 A5 JP 2023524102A5
Authority
JP
Japan
Prior art keywords
antibody
seq
abcb5
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524102A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030342 external-priority patent/WO2021222861A1/en
Publication of JP2023524102A publication Critical patent/JP2023524102A/ja
Publication of JP2023524102A5 publication Critical patent/JP2023524102A5/ja
Pending legal-status Critical Current

Links

JP2022566628A 2020-04-30 2021-04-30 Abcb5に特異的な抗体およびその使用 Pending JP2023524102A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018440P 2020-04-30 2020-04-30
US63/018,440 2020-04-30
PCT/US2021/030342 WO2021222861A1 (en) 2020-04-30 2021-04-30 Antibodies specific to abcb5 and uses thereof

Publications (2)

Publication Number Publication Date
JP2023524102A JP2023524102A (ja) 2023-06-08
JP2023524102A5 true JP2023524102A5 (cg-RX-API-DMAC7.html) 2024-05-13

Family

ID=78373989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566628A Pending JP2023524102A (ja) 2020-04-30 2021-04-30 Abcb5に特異的な抗体およびその使用

Country Status (8)

Country Link
US (1) US20230203153A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142793A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023524102A (cg-RX-API-DMAC7.html)
KR (1) KR20230034944A (cg-RX-API-DMAC7.html)
CN (1) CN116096753A (cg-RX-API-DMAC7.html)
AU (1) AU2021262864A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181591A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021222861A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097875A1 (en) 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
CN114828861A (zh) * 2019-10-10 2022-07-29 亚利桑那州立大学董事会 表达多特异性免疫细胞接合器的溶瘤病毒
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
JPWO2025004683A1 (cg-RX-API-DMAC7.html) * 2023-06-30 2025-01-02

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411101C (en) * 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
PL2155248T3 (pl) * 2007-04-12 2015-12-31 Brigham & Womens Hospital Inc Celowanie w ABCB5 w terapii nowotworowej
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
US20180134771A1 (en) * 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
JP7849972B2 (ja) * 2019-03-28 2026-04-22 ザ チルドレンズ メディカル センター コーポレーション 高機能な製造されたabcb5+間葉系幹細胞

Similar Documents

Publication Publication Date Title
US12122830B1 (en) Anti-ROR1 antibody and use thereof
JP7150880B2 (ja) 抗-b7-h3抗体およびその用途
JP2019116474A5 (cg-RX-API-DMAC7.html)
US9758586B2 (en) Chimeric rabbit/human ROR1 antibodies
JP2022541435A5 (cg-RX-API-DMAC7.html)
US20230391882A1 (en) Combination treatment
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2019535670A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2023511774A5 (cg-RX-API-DMAC7.html)
AU2016233495A2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP2019518068A (ja) グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
JP2018522888A5 (cg-RX-API-DMAC7.html)
JP2020533004A5 (cg-RX-API-DMAC7.html)
JP2022527151A5 (cg-RX-API-DMAC7.html)
JP2022523710A5 (cg-RX-API-DMAC7.html)
JP2020534012A5 (cg-RX-API-DMAC7.html)
JP2019512207A5 (cg-RX-API-DMAC7.html)
KR20220111308A (ko) 인간화 cldn18.2 항체
CN114634569A (zh) 高亲和力b7-h6抗体和抗体片段
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2022553922A5 (cg-RX-API-DMAC7.html)
JP2023537002A5 (cg-RX-API-DMAC7.html)
JP2022548043A5 (cg-RX-API-DMAC7.html)
JP2024506550A5 (cg-RX-API-DMAC7.html)